Non-coding RNA within extracellular vesicle in pathogenesis of hepatocellular carcinoma

doi:10.16139/j.1007-9610.2020.05.020

Abstract

CLC Number:

R735.7

CHEN Peng, LI Tao. Non-coding RNA within extracellular vesicle in pathogenesis of hepatocellular carcinoma[J]. Journal of Surgery Concepts & Practice, 2020, 25(05): 447-451.

Figures/Tables 1

ncRNA	染色体定位	作用
miR-196b-5p↑^[13]	chr6	促进肿瘤的血管和神经侵袭,增大肿瘤体积
miR-885-5p↓^[14]	chr2	作用于HK2-3’UTR,Warburg效应影响乳酸代谢,抑制肿瘤细胞的糖酵解
miR-122↓^[15]	chr18q21.31	靶向调控IGF-1R作用于RAS/RAF/ERK信号通路,导致肝癌细胞对索拉非尼耐药
miR‐26b↑^[16]	chr2q35	抑制ZNRD-1转录活性,激活Wnt/β-catenin信号通路,促进肿瘤的增殖
miR -26a↑^[17]	chr3p22.2	靶向抑制人肝癌的Mcl1,诱导p53介导的线粒体凋亡
miR-210↑^[18]	chr11p15.5	诱导内皮细胞分化,增加血管密度,促进肝癌细胞增殖
miR-638↓^[19]	chr17	肿瘤标志物,提示预后较差
miR-148b↑^[20]	chr12q13.13	抑制肿瘤中CSF1产生和释放,抑制巨噬细胞向肿瘤组织浸润
miR-21↑^[21]	chr17q23.1	作用于PTEN,激活PDK1/AKT信号通路,肝细胞星形细胞转化为癌相关成纤维细胞
miR-25-5p↑^[22]	chr7q22.1	下调LRRC7蛋白的表达来增强肿瘤细胞的跨内皮运动能力
lncRNA HULC↑^[25]	chr6p24.3	抑制p18的活性,促性肿瘤增殖
lncRNA-ATB↑^[28]	chr14	通过IL-11以及STAT3信号通路促进肿瘤侵袭、转移
lncRNA-HOTAIR↑^[30]	chr12q13.13	在多种肿瘤组织中过表达,与多种肿瘤增殖有关
lncRNA-HEIH↑^[31-32]	chr14q32.3	与EZH2的增强子相互作用,抑制细胞周期蛋白依赖蛋白激酶抑制剂EZh2目标基因p15、p16和p57的活性
lncRNA -FAL1↑^[33,35]	chr4	作为分子海绵结合miR-1236,抑制HDAC3与SENP1的表达,调节缺氧导致的上皮细胞-间充质转化和细胞增殖
lncRNA-UBE2CP3↑^[37]	chr4q12	通过ERK1/2/HIF-1α/VEGFA通路促进VEGFA表达而增强肿瘤血管侵袭性
lncRNA-OGFRP1↓^[38]	chr22q13.2	下调 AKT/mTOR信号通路抑制肝癌
lncRNA-PTTG3P^[39]	chr8p13.1	激活PTTG1与PI3K/AKT信号通路调控肿瘤生长
lncRNA-00364^[40]	chr13q21.32	调整p-STAT3-IFIT2抑制肝癌
lncRNA ZEB1-AS1↑ lncRNA ZFAS1↑^[41-42]	chr10p11.22 chr20q13.13	在肝癌细胞系及肝癌组织中表达均明显上调,通过不同分子机制参与肝癌侵袭、转移
lncRNA-TUC339↑^[43]	chr12	EV介导lncRNA转移,进而调节肿瘤细胞的局部微环境
lncRNA-linc-VLDLR^[44]	chr9p24.2	有助于影响细胞内应激反应水平,与肝癌细胞的化疗耐药相关
lncRNA-linc-RoR^[4]	chr18q21.31	参与肝癌缺氧机制的信号调节
lncRNA CACNA1G-AS1^[45]	chr17q21.33	表达产物竞争性地与miR-2392结合,提升肝癌的转化
lncRNA MAGI2-AS3^[46]	chr7q21.11	作为miR-374b-5p的互补双链,竞争性抑制miR-374b-5p的表达水平阻断肝癌转化
lncRNA-SNHG5↑^[47]	chr6q14.3	竞争性结合miR-26a-5p,调节GSK3β的表达,激活Wnt/β-catenin通路,诱导上皮细胞-间充质转化

References 47

[1]	Povero D, Eguchi A, Li H, et al. Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease[J]. PLoS One, 2014, 9(12):e113651.
[2]	Tkach M, Théry C. Communication by extracellular vesicles: where we are and where we need to go[J]. Cell, 2016, 164(6):1226-1232.
[3]	Luzio JP, Gray SR, Bright NA. Endosome-lysosome fusion[J]. Biochem Soc Trans, 2010, 38(6):1413-1416.
[4]	Takahashi K, Yan IK, Wood J, et al. Involvement of extracellular vesicle long noncoding RNA (linc-VLDLR) in tumor cell responses to chemotherapy[J]. Mol Cancer Res, 2014, 12(10):1377-1387. doi: 10.1158/1541-7786.MCR-13-0636 pmid: 24874432
[5]	Zhang J, Li S, Li L, et al. Exosome and exosomal micro-RNA: trafficking, sorting, and function[J]. Genomics Pro-teomics Bioinformatics, 2015, 13(1):17-24.
[6]	Yu S, Cao H, Shen B, et al. Tumor-derived exosomes in cancer progression and treatment failure[J]. Oncotarget, 2015, 6(35):37151-37168.
[7]	Buck AH, Coakley G, Simbari F, et al. Erratum: exosomes secreted by nematode parasites transfer small RNAs to mammalian cells and modulate innate immunity[J]. Nat Commun, 2015, 6:8772. doi: 10.1038/ncomms9772 pmid: 26490107
[8]	Kogure T, Lin WL, Yan IK, et al. Intercellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth[J]. Hepatology, 2011, 54(4):1237-1248.
[9]	Fu X, Liu M, Qu S, et al. Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway[J]. J Exp Clin Cancer Res, 2018, 37(1):52.
[10]	Lee HY, Chen CK, Ho CM, et al. EIF3C-enhanced exosome secretion promotes angiogenesis and tumorigenesis of human hepatocellular carcinoma[J]. Oncotarget, 2018, 9(17):13193-13205.
[11]	Tu T, Budzinska MA, Maczurek AE, et al. Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development[J]. Int JMol Sci, 2014, 15(6):9422-9458.
[12]	Wei L, Wang X, Lv L, et al. The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma[J]. Mol Cancer, 2019, 18(1):147.
[13]	Zhang L, Luo B, Dang YW, et al. Clinical significance of microRNA-196b-5p in hepatocellular carcinoma and its potential molecular mechanism[J]. J Cancer, 2019, 10(22):5355-5370. doi: 10.7150/jca.29293 pmid: 31632480
[14]	Xu F, Yan JJ, Gan Y, et al. miR-885-5p negatively regulates Warburg effect by silencing hexokinase 2 in liver cancer[J]. Mol Ther Nucleic Acids, 2019, 18:308-319.
[15]	Xu Y, Huang J, Ma L, et al. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways[J]. Cancer Lett, 2016, 371(2):171-181.
[16]	Hu X, Wang R, Ren Z, et al. MiR-26b suppresses hepatocellular carcinoma development by negatively regulating ZNRD1 and Wnt/beta-catenin signaling[J]. Cancer Med, 2019, 8(17):7359-7371.
[17]	Gao XM, Zhu Y, Li JH, et al. microRNA-26a induces a mitochondrial apoptosis mediated by p53 through targeting to inhibit Mcl1 in human hepatocellular carcinoma[J]. Onco Targets Ther, 2018, 11:2227-2239.
[18]	Lin XJ, Fang JH, Yang XJ, et al. Hepatocellular carcinoma cell-secreted exosomal microRNA-210 promotes angiogenesis in vitro and in vivo[J]. Mol Ther Nucleic Acids, 2018, 11:243-252..
[19]	Shi M, Jiang Y, Yang L, et al. Decreased levels of serum exosomal miR-638 predict poor prognosis in hepatocellular carcinoma[J]. J Cell Biochem, 2018, 119(6):4711-4716.
[20]	Ke M, Zhang Z, Cong L, et al. MicroRNA-148b-colony-stimulating factor-1 signaling-induced tumor-associated macrophage infiltration promotes hepatocellular carcinoma metastasis[J]. Biomed Pharmacother, 2019, 120:109523.
[21]	Zhou Y, Ren H, Dai B, et al. Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancer-associated fibroblasts[J]. J Exp Clin Cancer Res, 2018, 37(1):324.
[22]	Liu H, Chen W, Zhi X, et al. Tumor-derived exosomes promote tumor self-seeding in hepatocellular carcinoma by transferring miRNA-25-5p to enhance cell motility[J]. Oncogene, 2018, 37(36):4964-4978.
[23]	Yu FJ, Zheng JJ, Dong PH, et al. Long non-coding RNAs and hepatocellular carcinoma[J]. Mol Clin Oncol, 2015, 3(1):13-17.
[24]	Panzitt K, Tschernatsch MMO, Guelly C, et al. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA[J]. Gastroenterology, 2007, 132(1):330-342. pmid: 17241883
[25]	Du Y, Kong G, You X, et al. Elevation of highly up-regulated in liver cancer (HULC) by hepatitis B virus X protein promotes hepatoma cell proliferation via down-regulating p18[J]. J Biol Chem, 2012, 287(31):26302-26311.
[26]	Iizuka N, Oka M, Yamada-Okabe H, et al. Comparison of gene expression profiles between hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method[J]. Cancer Res, 2002, 62(14):3939-3944. pmid: 12124323
[27]	Kim KS, Lee YI. Biallelic expression of the H19 and IGF2 genes in hepatocellular carcinoma[J]. Cancer Lett, 1997, 119(2):143-148. pmid: 9570364
[28]	Yuan JH, Yang F, Wang F, et al. A long noncoding RNA activated by TGF-β promotes the invasion-metastasis cascade in hepatocellular carcinoma[J]. Cancer Cell, 2014, 25(5):666-681.
[29]	He Y, Meng XM, Huang C, et al. Long noncoding RNAs: novel insights into hepatocelluar carcinoma[J]. Cancer Lett, 2014, 344(1):20-27.
[30]	Yang Z, Zhou L, Wu LM, et al. Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation[J]. Ann Surg Oncol, 2011, 18(5):1243-1250. doi: 10.1245/s10434-011-1581-y pmid: 21327457
[31]	Yang F, Zhang L, Huo XS, et al. Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans[J]. Hepatology, 2011, 54(5):1679-1689. doi: 10.1002/hep.24563 pmid: 21769904
[32]	Zhang C, Yang X, Qi Q, et al. lncRNA-HEIH in serum and exosomes as a potential biomarker in the HCV-related hepatocellular carcinoma[J]. Cancer Biomark, 2018, 21(3):651-659. doi: 10.3233/CBM-170727 pmid: 29286922
[33]	Li B, Mao R, Liu C, et al. LncRNA FAL11 promotes cell proliferation and migration by acting as a CeRNA of miR-1236 in hepatocellular carcinoma cells[J]. Life Sci, 2018, 197:122-129.
[34]	Liu T, Chi H, Chen J, et al. Curcumin suppresses prolife-ration and in vitro invasion of human prostate cancer stem cells by ceRNA effect of miR-145 and lncRNA-ROR[J]. Gene, 2017, 631:29-38. doi: S0378-1119(17)30645-5 pmid: 28843521
[35]	Chen SY, Teng SC, Cheng TH, et al. miR-1236 regulates hypoxia-induced epithelial-mesenchymal transition and cell migration/invasion through repressing SENP1 and HDAC3[J]. Cancer Lett, 2016, 378(1):59-67.
[36]	Xu H, Chen Y, Dong X, et al. Serum exosomal long noncoding RNAs ENSG00000258332.1 and LINC00635 for the diagnosis and prognosis of hepatocellular carcinoma[J]. Cancer Epidemiol Biomarkers Prev, 2018, 27(6):710-716.
[37]	Lin J, Cao S, Wang Y, et al. Long non-coding RNA UBE2CP3 enhances HCC cell secretion of VEGFA and promotes angiogenesis by activating ERK1/2/HIF-1α/VEGFA signalling in hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2018, 37(1):113.
[38]	Chen W, You J, Zheng Q, et al. Downregulation of lnc-RNA OGFRP1 inhibits hepatocellular carcinoma progression by AKT/mTOR and Wnt/β-catenin signaling pathways[J]. Cancer Manag Res, 2018, 10:1817-1826. doi: 10.2147/CMAR.S164911 pmid: 29997441
[39]	Huang JL, Cao SW, Ou QS, et al. The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma[J]. Mol Cancer, 2018, 17(1):93.
[40]	Tang WG, Hu B, Sun HX, et al. Long non-coding RNA00364 represses hepatocellular carcinoma cell proli-feration via modulating p-STAT3-IFIT2 signaling axis[J]. Oncotarget, 2017, 8(60):102006-102019.
[41]	Li T, Xie J, Shen C, et al. Amplification of long noncoding RNA ZFAS1 promotes metastasis in hepatocellular carcinoma[J]. Cancer Res, 2015, 75(15):3181-3191.
[42]	Li T, Xie J, Shen C, et al. Upregulation of long noncoding RNA ZEB1-AS1 promotes tumor metastasis and predicts poor prognosis in hepatocellular carcinoma[J]. Oncogene, 2015, 35(12):1575-1584.
[43]	Kogure T, Yan IK, Lin WL, et al. Extracellular vesicle-mediated transfer of a novel long noncoding RNA TUC339: a mechanism of intercellular signaling in human hepatocellular cancer[J]. Genes Cancer, 2013, 4(7-8):261-272.
[44]	Takahashi K, Yan IK, Haga H, et al. Modulation of hypoxia-signaling pathways by extracellular linc-RoR[J]. J Cell Sci, 2014, 127(Pt7):1585-1594.
[45]	Yang J, Li C, Li H, et al. LncRNA CACNA1G-AS1 facilitates hepatocellular carcinoma progression through the miR-2392/C1orf61 pathway[J]. J Cell Physiol, 2019, 234(10):18415-18422.
[46]	Yin Z, Ma T, Yan J, et al. LncRNA MAGI2-AS3 inhibits hepatocellular carcinoma cell proliferation and migration by targeting the miR-374b-5p/SMG1 signaling pathway[J]. J Cell Physiol, 2019, 234(10):18825-18836. doi: 10.1002/jcp.28521 pmid: 30924168
[47]	Li Y, Guo D, Zhao Y, et al. Long non-coding RNA SNHG5 promotes human hepatocellular carcinoma progression by regulating miR-26a-5p/GSK3beta signal pathway[J]. Cell Death Dis, 2018, 9(9):888.

Non-coding RNA within extracellular vesicle in pathogenesis of hepatocellular carcinoma

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 47

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	YE Feng, GONG Xiaoyong, REN Jiajun, CAI Qiang, CHEN Sheng. Application of ERCP in diagnosis and treatment of biliary complications during perioperative period of primary liver cancer [J]. Journal of Surgery Concepts & Practice, 2023, 28(04): 355-360.
[2]	CHANG Jessica, CHEN Xuxiao, CHEN Yongjun. Role of the spleen in patients with liver cancer and cirrhosis [J]. Journal of Surgery Concepts & Practice, 2023, 28(04): 394-398.
[3]	ZHANG Hui, GONG Ling, GUO Qian, LUO Yan. Retrospective study on sugammadex for reversal of neuromuscular blockade after radiofrequency ablation of hepatic carcinoma under general anesthesia [J]. Journal of Surgery Concepts & Practice, 2023, 28(01): 72-76.
[4]	ZHANG Jixiang, XIE Zhihua, LI Wei, JIANG Xiaoqing. Classification of intrahepatic cholangiocarcinoma and hot topics in surgical treatment [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 478-482.
[5]	YIN Yanjiang, LUO Zhiwen, CHEN Xiao, ZHANG Yefan, HUANG Zhen, ZHAO Hong, ZHAO Jianjun, LI Zhiyu, ZHOU Jianguo, CAI Jianqiang, BI Xinyu. Relationship between surgical margin and prognosis of patients with intrahepatic cholangiocarcinoma [J]. Journal of Surgery Concepts & Practice, 2022, 27(03): 221-228.
[6]	CHEN Congyan, WANG Junqing, CHEN Yongjun. Gut microbiota and mechanism of liver cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(03): 256-260.
[7]	ZHU Peng, LIAO Wei, ZHANG Bixiang, CHEN Xiaoping. Robotic hepatectomy for liver cancer: application status and future prospect [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 95-99.
[8]	TANG Zhaoyou. Enlightenment of Chinese philosophic thinking on treatment of liver cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 93-94.
[9]	REN Jiajun, CHEN Yongjun. Simultaneous hepatectomy and splenectomy in treatment of portal hypertension and hypersplenism complicated by primary liver cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 139-144.
[10]	SUN Huichuan. Current status and perspectives of conversion therapy for hepatocellular carcinoma [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 134-138.
[11]	MA Jingqin, YANG Minjie, YAN Zhiping. Precision transarterial chemoembolization: treatment goal and embolic endpoint [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 131-133.
[12]	BAO Quan, XING Baocai. Surgical treatment strategy for complex bilateral multiple liver metastases of colorectal carcinoma [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 128-130.
[13]	CAO Jun, CHEN Yajin. Laparoscopic anatomic hepatectomy in treatment of hepatocellular carcinoma: standardization and think deeply [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 123-127.
[14]	FENG Hao, LÜ Zicheng, XIA Qiang. Liver transplantation in treatment of hepatocellular carcinoma: management of whole⁃process and progress in treatment [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 119-122.
[15]	HUANG Jiwei, QIU Guoteng, ZENG Yong. Advances in surgical treatment of hepatocellular carcinoma [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 113-118.